TABLE 2.
Inhibition by LP-40 and control peptides of HIV-1 Env-mediated cell entry and fusiona
| Primary Env | Subtype | Inhibitionc (IC50 [nM]) of: |
|||||
|---|---|---|---|---|---|---|---|
| Viral entry |
Cell fusion |
||||||
| T20 | LP-40 | LP-11 | T20 | LP-40 | LP-11 | ||
| 92UG037.8 | A | 5.36 ± 0.53 | 2.47 ± 0.12 | 0.92 ± 0.05 | 4.7 ± 0.62 | 0.14 ± 0.04 | 0.98 ± 0.26 |
| 92RW020 | A | 1.215 ± 0.28 | 1.32 ± 0.13 | 0.84 ± 0.04 | 0.81 ± 0.17 | 0.01 ± 0 | 0.28 ± 0.06 |
| 398-F1_F6_20b | A | 12.69 ± 1.3 | 3.58 ± 0.27 | 0.5 ± 0.02 | 7.2 ± 0.08 | 0.12 ± 0.04 | 3.25 ± 0.49 |
| AC10.0.29 | B | 3.55 ± 0.26 | 1.94 ± 0.53 | 0.47 ± 0.02 | 2.59 ± 0.51 | 0.06 ± 0.02 | 0.66 ± 0.06 |
| SC422661.8 | B | 20.65 ± 4.44 | 18.68 ± 4.24 | 0.28 ± 0 | 2.32 ± 0.29 | 0.1 ± 0.01 | 0.53 ± 0.08 |
| TRO.11b | B | 8.18 ± 0.62 | 3.49 ± 0.48 | 0.99 ± 0.01 | 24.12 ± 7.12 | 0.54 ± 0.15 | 2.53 ± 0.6 |
| BJOX002000.03.2b | B | 34.38 ± 3.6 | 3.35 ± 0.88 | 0.96 ± 0.02 | 1.66 ± 0.59 | 0.06 ± 0.01 | 0.4 ± 0.1 |
| X2278_C2_B6b | B | 6.42 ± 0.2 | 1.82 ± 0.8 | 0.16 ± 0 | 4.57 ± 1.11 | 0.17 ± 0.09 | 1.94 ± 0.35 |
| B02 | B' | 7.7 ± 0.18 | 0.91 ± 0.16 | 1.26 ± 0.11 | 4.89 ± 0.4 | 0.06 ± 0.02 | 0.9 ± 0.10 |
| B04 | B' | 5.01 ± 0.68 | 1.14 ± 0.14 | 0.79 ± 0.03 | 8 ± 2.11 | 0.15 ± 0.01 | 2.09 ± 0.81 |
| CAP45.2.00.G3 | C | 170.9 ± 2.46 | 21.74 ± 2.46 | 0.98 ± 0.01 | 25.37 ± 5.42 | 0.68 ± 0.09 | 2.7 ± 0.14 |
| ZM53 M.PB12 | C | 34.00 ± 5.57 | 4.63 ± 0.27 | 1.04 ± 0.02 | 38.79 ± 8.12 | 0.22 ± 0.06 | 2.17 ± 0.91 |
| HIV_25710-2.43b | C | 14.73 ± 0.74 | 4.35 ± 0.53 | 0.4 ± 0 | 13.75 ± 2.89 | 0.08 ± 0.01 | 0.59 ± 0.09 |
| CE1176_A3b | C | 4.66 ± 0.24 | 1.58 ± 0.43 | 0.81 ± 0.01 | 5.73 ± 1.58 | 0.09 ± 0.01 | 1.57 ± 0.08 |
| CE703010217_B6b | C | 43.11 ± 9.81 | 3.52 ± 0.53 | 0.65 ± 0.01 | 6.23 ± 0.47 | 0.09 ± 0 | 0.31 ± 0.05 |
| X1632-S2-B10b | G | 15.49 ± 0.98 | 2.27 ± 0.13 | 1.08 ± 0.11 | 6.78 ± 1 | 0.22 ± 0.09 | 1.02 ± 0.11 |
| 246_F3_C10_2b | A/C | 41.24 ± 4.17 | 3.89 ± 0.21 | 0.84 ± 0.02 | 4.1 ± 0.91 | 0.11 ± 0.01 | 2.46 ± 0.28 |
| AE03 | A/E | 8.66 ± 0.56 | 3.62 ± 0.63 | 0.75 ± 0.04 | 17.45 ± 1.95 | 0.16 ± 0.01 | 2.19 ± 0.34 |
| AE04 | A/E | 11.72 ± 0.67 | 0.81 ± 0.07 | 1.38 ± 0.12 | 24.57 ± 3.59 | 0.21 ± 0.05 | 3.01 ± 0.33 |
| CNE8b | A/E | 35.24 ± 4.8 | 3.46 ± 0.55 | 0.76 ± 0.01 | 33.96 ± 7.12 | 0.23 ± 0.09 | 3.97 ± 0.23 |
| CNE55b | A/E | 23 ± 1.45 | 2.68 ± 0.44 | 0.45 ± 0.01 | 9.77 ± 1.12 | 0.06 ± 0.01 | 1.62 ± 0.85 |
| CH64.20 | B/C | 50.69 ± 8.86 | 4.98 ± 0.1 | 0.5 ± 0.02 | 3.15 ± 0.28 | 0.18 ± 0.06 | 0.62 ± 0.12 |
| CH070.1 | B/C | 80.8 ± 3.89 | 3.83 ± 0.08 | 1.33 ± 0.08 | 13.08 ± 2.45 | 1.08 ± 0.06 | 3.89 ± 0.86 |
| CH119.10b | B/C | 22.84 ± 1.6 | 2.22 ± 0.19 | 0.79 ± 0.02 | 2.63 ± 0.52 | 0.04 ± 0.01 | 0.81 ± 0.13 |
| CH120.6 | B/C | 74.06 ± 3.63 | 4.95 ± 0.56 | 1.93 ± 0.12 | 9.89 ± 0.52 | 0.18 ± 0.04 | 1.49 ± 0.42 |
| Mean | 29.45 | 4.29 | 0.83 | 11.31 | 0.20 | 1.68 | |
a
The assay was performed in triplicate and repeated 3 times.
b
A global panel of HIV-1 isolates representing the genetic and antigenic diversities worldwide.
c
The data are expressed as means ± standard deviations.